Merck, BMS Target Aurobindo Over Generic HIV Drug

Law360, New York (September 13, 2013, 1:36 PM EDT) -- Merck Sharp & Dohme Corp. and Bristol-Myers Squibb Co. sued Aurobindo Pharma Ltd. in New Jersey federal court on Wednesday, alleging the Indian drugmaker is trying to introduce its own version of HIV treatment Sustiva before the drugs' patents expire.

The pharmaceuticals giants' suit says Aurobindo is infringing three patents related to the HIV drug through its submission of an abbreviated new drug application seeking U.S. Food and Drug Administration approval to make generic form of Sustiva.

Merck is the assignee of two of the patents,...
To view the full article, register now.